BMO Capital Markets Reaffirms Outperform Rating for Merck & Company, Inc. (MRK)

BMO Capital Markets restated their outperform rating on shares of Merck & Company, Inc. (NYSE:MRK) in a research note published on Monday, July 24th. The firm currently has a $73.00 target price on the stock, down from their prior target price of $74.00.

A number of other brokerages have also weighed in on MRK. BidaskClub lowered Merck & from a sell rating to a strong sell rating in a research report on Wednesday, July 19th. Zacks Investment Research lowered Merck & from a buy rating to a hold rating in a research report on Thursday, May 25th. Jefferies Group LLC reaffirmed a sell rating and set a $51.00 target price on shares of Merck & in a research report on Wednesday, May 24th. Vetr lowered Merck & from a strong-buy rating to a buy rating and set a $69.99 price target for the company. in a research report on Wednesday, May 17th. Finally, Citigroup Inc. set a $65.00 price target on Merck & and gave the stock a hold rating in a research report on Wednesday, July 5th. Two analysts have rated the stock with a sell rating, nine have assigned a hold rating and twelve have given a buy rating to the company. The company presently has an average rating of Hold and an average target price of $69.58.

Shares of Merck & (NYSE:MRK) opened at 61.49 on Monday. Merck & has a 1-year low of $58.29 and a 1-year high of $66.80. The firm has a market capitalization of $167.71 billion, a P/E ratio of 33.29 and a beta of 0.80. The stock has a 50 day moving average of $62.91 and a 200-day moving average of $63.83.

Merck & (NYSE:MRK) last posted its quarterly earnings data on Friday, July 28th. The company reported $1.01 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.87 by $0.14. Merck & had a return on equity of 26.02% and a net margin of 17.14%. The company had revenue of $9.93 billion during the quarter, compared to analysts’ expectations of $9.75 billion. During the same quarter in the previous year, the business earned $0.93 EPS. Merck &’s revenue was up .9% compared to the same quarter last year. On average, equities analysts expect that Merck & will post $3.87 earnings per share for the current year.

TRADEMARK VIOLATION WARNING: “BMO Capital Markets Reaffirms Outperform Rating for Merck & Company, Inc. (MRK)” was first published by Week Herald and is the property of of Week Herald. If you are accessing this article on another site, it was copied illegally and republished in violation of U.S. and international trademark and copyright law. The correct version of this article can be viewed at https://weekherald.com/2017/08/19/merck-co-s-mrk-outperform-rating-reaffirmed-at-bmo-capital-markets-updated-updated-updated.html.

The business also recently declared a quarterly dividend, which will be paid on Friday, October 6th. Investors of record on Friday, September 15th will be issued a $0.47 dividend. The ex-dividend date of this dividend is Thursday, September 14th. This represents a $1.88 annualized dividend and a dividend yield of 3.06%. Merck &’s dividend payout ratio is presently 76.11%.

Several large investors have recently bought and sold shares of MRK. Krilogy Financial LLC boosted its stake in Merck & by 0.4% in the second quarter. Krilogy Financial LLC now owns 3,129 shares of the company’s stock valued at $201,000 after buying an additional 11 shares in the last quarter. HM Capital Management LLC boosted its stake in Merck & by 0.4% in the first quarter. HM Capital Management LLC now owns 3,734 shares of the company’s stock valued at $236,000 after buying an additional 15 shares in the last quarter. Balentine LLC boosted its stake in Merck & by 1.0% in the second quarter. Balentine LLC now owns 2,107 shares of the company’s stock valued at $135,000 after buying an additional 20 shares in the last quarter. RB Capital Management LLC boosted its stake in Merck & by 0.5% in the second quarter. RB Capital Management LLC now owns 4,587 shares of the company’s stock valued at $294,000 after buying an additional 23 shares in the last quarter. Finally, Baystate Wealth Management LLC boosted its stake in Merck & by 0.4% in the second quarter. Baystate Wealth Management LLC now owns 6,470 shares of the company’s stock valued at $405,000 after buying an additional 27 shares in the last quarter. 73.46% of the stock is owned by hedge funds and other institutional investors.

Merck & Company Profile

Merck & Co, Inc is a global healthcare company. The Company offers health solutions through its prescription medicines, vaccines, biologic therapies and animal health products. It operates through four segments: Pharmaceutical, Animal Health, Healthcare Services and Alliances. The Company’s Pharmaceutical segment includes human health pharmaceutical and vaccine products marketed either directly by the Company or through joint ventures.

Analyst Recommendations for Merck & (NYSE:MRK)




Receive News & Ratings for Merck & Company Inc. Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Merck & Company Inc. and related companies with MarketBeat.com’s FREE daily email newsletter.

Leave a Reply

Your email address will not be published. Required fields are marked *

*

six − 3 =